Statement Of Cash Flows [Abstract]

OSE Immunotherapeutics - Filing #831399

Concept 2023-01-01 to
2023-12-31
2022-01-01 to
2022-12-31
Statement of cash flows [abstract]
Cash flows from (used in) operating activities [abstract]
Increase (decrease) in working capital
835,000 EUR
3 142 EUR
Adjustments for increase (decrease) in other liabilities
464,000 EUR
Adjustments for decrease (increase) in other current assets
353,000 EUR
Adjustments for increase (decrease) in employee benefit liabilities
14,000 EUR
147,000 EUR
Cash flows from (used in) financing activities [abstract]
Payments for share issue costs
0 EUR
6,000 EUR

Talk to a Data Expert

Have a question? We'll get back to you promptly.